Patents by Inventor Takuo Tsukuda

Takuo Tsukuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4?-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 8648054
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 11, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20130237491
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: April 12, 2013
    Publication date: September 12, 2013
    Applicant: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • Macrocyclic compound
    Patent number: 8362236
    Abstract: The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 29, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Nobuo Shimma, Takuo Tsukuda, Hiroshi Koyano, Atsushi Suda, Tadakatsu Hayase, Kihito Hada, Ken-Ichi Kawasaki, Susumu Komiyama, Naomi Ono, Toshikazu Yamazaki, Ryoichi Saitoh, Masami Kohchi, Kiyoshi Hasegawa
  • HSP90 inhibitor
    Patent number: 8193351
    Abstract: Compounds represented by formula (1) shown below, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such compounds are provided.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: June 5, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takuo Tsukuda, Ken-Ichi Kawasaki, Susumu Komiyama, Yoshiaki Isshiki, Yasuhiko Shiratori, Kiyoshi Hasegawa, Takaaki Fukami, Takaaki Miura, Naomi Ono, Toshikazu Yamazaki, Young-Jun Na, Dong-Oh Yoon, Sung-Jin Kim
  • 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20120034184
    Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 17, 2011
    Publication date: February 9, 2012
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4?-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 8071567
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: December 6, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • Intermediate compound for synthesis of viridiofungin a derivative
    Patent number: 8030496
    Abstract: A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH2)m—R?, etc.; and n represents an integer of 0 to 10.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: October 4, 2011
    Assignee: Chugai Seiyaki Kabushiki Kaisha
    Inventors: Tatsuya Kato, Nobuaki Kimura, Akemi Mizutani, Toshihiko Makino, Kenichi Kawasaki, Hiroshi Fukuda, Susumu Komiyama, Takuo Tsukuda
  • 4?-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 7915232
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are useful for treating a patient suffering from a HCV infection and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: March 29, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
  • Intermediate compound for synthesis of viridiofungin a derivative
    Patent number: 7897783
    Abstract: A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): [wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH2)m—R?, etc.; and n represents an integer of 0 to 10].
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: March 1, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tatsuya Kato, Nobuaki Kimura, Akemi Mizutani, Toshihiko Makino, Kenichi Kawasaki, Hiroshi Fukuda, Susumu Komiyama, Takuo Tsukuda
  • Virus therapeutic drug
    Publication number: 20100274026
    Abstract: The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and since they also only demonstrate mild cytotoxicity in vivo, a pharmaceutical composition containing the compound of the present invention is extremely useful as an anti-HCV preventive/therapeutic agent.
    Type: Application
    Filed: July 6, 2010
    Publication date: October 28, 2010
    Inventors: Masahiro Aoki, Hideyuki Kato, Masayuki Sudoh, Takuo Tsukuda, Miyako Masubuchi, Kenichi Kawasaki
  • Remedy for viral disease
    Patent number: 7776918
    Abstract: The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and since they also only demonstrate mild cytotoxicity in vivo, a pharmaceutical composition containing the compound of the present invention is extremely useful as an anti-HCV preventive/therapeutic agent.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: August 17, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masahiro Aoki, Hideyuki Kato, Masayuki Sudoh, Takuo Tsukuda, Miyako Masubuchi, Kenichi Kawasaki
  • Intermediate compound for synthesis of viridiofungin a derivative
    Publication number: 20100152457
    Abstract: A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH2)m—R?, etc.; and n represents an integer of 0 to 10.
    Type: Application
    Filed: February 4, 2010
    Publication date: June 17, 2010
    Inventors: Tatsuya Kato, Nobuaki Kimura, Akemi Mizutani, Toshihiko Makino, Kenichi Kawasaki, Hiroshi Fukuda, Susumu Komiyama, Takuo Tsukuda
  • Intermediate compound for synthesis of viridiofungin a derivative
    Publication number: 20100152456
    Abstract: A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH2)m—R?, etc.; and n represents an integer of 0 to 10.
    Type: Application
    Filed: February 4, 2010
    Publication date: June 17, 2010
    Inventors: Tatsuya Kato, Nobuaki Kimura, Akemi Mizutani, Toshihiko Makino, Kenichi Kawasaki, Hiroshi Fukuda, Susumu Komiyama, Takuo Tsukuda
  • Macrocyclic Compound
    Publication number: 20100056510
    Abstract: The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.
    Type: Application
    Filed: February 29, 2008
    Publication date: March 4, 2010
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Nobuo Shimma, Takuo Tsukuda, Hiroshi Koyano, Atsushi Suda, Tadakatsu Hayase, Kihito Hada, Ken-ichi Kawasaki, Susumu Komiyama, Naomi Ono, Toshikazu Yamazaki, Ryoichi Saitoh, Masami Kohchi, Kiyoshi Hasegawa
  • 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20100003213
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 16, 2009
    Publication date: January 7, 2010
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
    Publication number: 20100004192
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 14, 2009
    Publication date: January 7, 2010
    Inventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
  • 4?-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 7608601
    Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • HSP90 Inhibitor
    Publication number: 20090247524
    Abstract: Compounds represented by formula (1) shown below, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such compounds are provided.
    Type: Application
    Filed: May 25, 2007
    Publication date: October 1, 2009
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Takuo Tsukuda, Ken-ichi Kawasaki, Susumu Komiyama, Yoshiaki Isshiki, Yasuhiko Shiratori, Kiyoshi Hasegawa, Takaaki Fukami, Takaaki Miura, Naomi Ono, Toshikazu Yamazaki, Young-Jun Na, Dong-Oh Yoon, Sung-Jin Kim
  • Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof
    Publication number: 20080293950
    Abstract: A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): [wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH2)m—R?, etc.; and n represents an integer of 0 to 10].
    Type: Application
    Filed: February 16, 2006
    Publication date: November 27, 2008
    Inventors: Tatsuya Kato, Nobuaki Kimura, Akemi Mizutani, Toshihiko Makino, Kenichi Kawasaki, Hiroshi Fukuda, Susumu Komiyama, Takuo Tsukuda
  • Compound having anti-HCV activity and process for producing the same
    Patent number: 7378446
    Abstract: The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I): (wherein A represents —(CH2)n—, etc.; B represents —(C?O)—, etc.; D represents —(CH2)m—R?, etc.; E represents a hydrogen atom, etc.; G represents —(CH2)p-J, etc.; bond Q represents a single bond or double bond; and R1, R2 and R3 may be the same or different and each represent a hydrogen atom, etc.), a prodrug thereof or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: May 27, 2008
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Sudoh, Takuo Tsukuda, Miyako Masubuchi, Kenichi Kawasaki, Takeshi Murata, Fumio Watanabe, Hiroshi Fukuda, Susumu Komiyama, Tadakatsu Hayase